Showing 141 - 160 results of 32,613 for search '(((( ((b large) OR (a large)) decrease ) OR ( i greater increase ))) OR ( c large decrease ))', query time: 1.26s Refine Results
  1. 141

    Table6_RAB39B as a Chemosensitivity-Related Biomarker for Diffuse Large B-Cell Lymphoma.XLSX by Cong Xu (203537)

    Published 2022
    “…<p>Background: Diffuse large B-cell lymphoma (DLBCL) is the most common aggressive lymphoma with an increased tendency to relapse or refractoriness. …”
  2. 142

    Table1_RAB39B as a Chemosensitivity-Related Biomarker for Diffuse Large B-Cell Lymphoma.DOCX by Cong Xu (203537)

    Published 2022
    “…<p>Background: Diffuse large B-cell lymphoma (DLBCL) is the most common aggressive lymphoma with an increased tendency to relapse or refractoriness. …”
  3. 143

    Table2_RAB39B as a Chemosensitivity-Related Biomarker for Diffuse Large B-Cell Lymphoma.XLSX by Cong Xu (203537)

    Published 2022
    “…<p>Background: Diffuse large B-cell lymphoma (DLBCL) is the most common aggressive lymphoma with an increased tendency to relapse or refractoriness. …”
  4. 144

    Table5_RAB39B as a Chemosensitivity-Related Biomarker for Diffuse Large B-Cell Lymphoma.XLSX by Cong Xu (203537)

    Published 2022
    “…<p>Background: Diffuse large B-cell lymphoma (DLBCL) is the most common aggressive lymphoma with an increased tendency to relapse or refractoriness. …”
  5. 145
  6. 146

    Table 1_Cholesterol metabolic reprogramming drives the onset of DLBCL and represents a promising therapeutic target.docx by Lili Zhou (265076)

    Published 2025
    “…</p>Methods<p>We retrospectively analyzed clinical data from 200 DLBCL patients and 185 healthy controls, focusing on lipid and lipoprotein levels, including triglycerides (TG), total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), apolipoprotein A1 (ApoA1), apolipoprotein B (ApoB), and apolipoprotein E (ApoE). …”
  7. 147

    Data Sheet 1_Cholesterol metabolic reprogramming drives the onset of DLBCL and represents a promising therapeutic target.docx by Lili Zhou (265076)

    Published 2025
    “…</p>Methods<p>We retrospectively analyzed clinical data from 200 DLBCL patients and 185 healthy controls, focusing on lipid and lipoprotein levels, including triglycerides (TG), total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), apolipoprotein A1 (ApoA1), apolipoprotein B (ApoB), and apolipoprotein E (ApoE). …”
  8. 148
  9. 149
  10. 150
  11. 151

    Illustration of decline in network accuracy associated with large window sizes, using simulated data. by Sam Tilsen (406665)

    Published 2021
    “…<p>(a, b) Simulated articulatory signals associated with simulated /p/ and /t/ onsets. …”
  12. 152
  13. 153

    Supplementary Material for: High-sensitivity Troponin I Measurement in a Large Contemporary Cohort: Implications for Clinical Care by Esau D. (20563829)

    Published 2025
    “…Laboratory data, blood pressure, and anthropomorphic measures were extracted from the electronic medical record Results: Remeasurement of hsTnI did not change risk category in 92.7% of cases. Male sex, higher HDL-C, higher Hgb A1c, decreasing eGFR, and increasing systolic blood pressure were significant predictors of increased hsTnI. …”
  14. 154
  15. 155
  16. 156

    Supplementary Material for: STAT3 Promotes Cell Proliferation by Potentiating the CCL4 Transcriptional Activity in Diffuse Large B-Cell Lymphoma by Xiao S. (11834801)

    Published 2021
    “…However, the underlying mechanism of STAT3 in the pathogenesis of diffuse large B-cell lymphoma (DLBCL) has yet to be established. …”
  17. 157
  18. 158
  19. 159

    Fig 2 - by Andrew T. Marshall (10159199)

    Published 2021
    Subjects:
  20. 160

    Prestroke Glucose Control and Functional Outcome in Patients With Acute Large Vessel Occlusive Stroke and Diabetes After Thrombectomy by Jun Young Chang (3716227)

    Published 2021
    “…Higher HbA1c levels at admission were significantly associated with decreased odds of favorable functional outcomes at a threshold of 7.0%–7.1%. …”